Tesamorelin
FDA-Referenced GHRH Analogue
Best For
Visceral fat reduction, metabolic health optimization
~20%
Reduction in visceral adipose tissue
FDA
Referenced in FDA-reviewed clinical trials
IGF-1
Consistent elevation in clinical settings
How It Works
Tesamorelin is a synthetic GHRH analogue that has been the subject of extensive clinical research, including FDA-reviewed trials for HIV-associated lipodystrophy. It stimulates pituitary GH release and has demonstrated consistent ability to reduce visceral adipose tissue while improving lipid profiles and cognitive markers in clinical settings.
Key Research Areas
Visceral Fat Reduction
Clinically proven ~20% reduction in visceral adipose
IGF-1 Optimization
Improves IGF-1 levels and lipid profiles
Cognitive Support
Emerging data on cognitive function improvement
Clinical Validation
Extensively studied in controlled trials
Research Highlights
- Clinically proven ~20% reduction in visceral adipose tissue
- Improves IGF-1 levels, lipid profiles, and cognitive function
Formulation Notes
Common concentrations referenced in published clinical studies:
[EL-1210]10mgCategory
Growth hormone naturally declines ~14% per decade after age 30. GH secretagogues and GHRH analogues stimulate the pituit...
Explore Renew category →Educational Content. This compound profile is for informational purposes only. Not intended as medical advice, diagnosis, or treatment.
Related Compounds
Sermorelin Acetate
GHRH(1-29) Analogue
- Stimulates natural, pulsatile GH release — not suppressive
- Improves sleep, body composition, and skin within 3-6 months
Reference Codes
[EL-1010]10mgHGH
Recombinant Somatotropin
- Direct GH replacement for muscle, fat, and regeneration
- Supports cellular regeneration, IGF-1 production, recovery
Reference Codes
[EL-1324]24iu